Abbott Labs Com (ABT) Position Maintained by First Long Island Investors Llc

February 15, 2018 - By Peter Erickson

Investors sentiment decreased to 0.87 in 2017 Q3. Its down 0.01, from 0.88 in 2017Q2. It fall, as 47 investors sold ABT shares while 563 reduced holdings. 111 funds opened positions while 421 raised stakes. 1.21 billion shares or 0.79% less from 1.22 billion shares in 2017Q2 were reported. Vigilant Capital Mngmt Limited Liability Corp has invested 1.82% of its portfolio in Abbott Laboratories (NYSE:ABT). Private Wealth Advisors holds 0.22% in Abbott Laboratories (NYSE:ABT) or 9,826 shares. Davenport And Communications reported 119,427 shares. Schulhoff & owns 24,809 shares for 0.79% of their portfolio. Independent stated it has 1.17% of its portfolio in Abbott Laboratories (NYSE:ABT). Glg Limited, New York-based fund reported 115,021 shares. Hyman Charles D has 0.26% invested in Abbott Laboratories (NYSE:ABT). Taurus Asset Mngmt Limited Liability Com, a New York-based fund reported 66,995 shares. Citadel Advsr Ltd Liability Corp has invested 0.17% in Abbott Laboratories (NYSE:ABT). 16,754 were reported by Mackenzie Financial. Baldwin Investment Mgmt Ltd Liability reported 20,500 shares. Fdx invested in 59,754 shares or 0.09% of the stock. Baker Ellis Asset Ltd reported 39,404 shares. Greatmark Prtnrs holds 5,942 shares. Annex Advisory Serv Llc holds 0.18% or 16,603 shares.

Since August 16, 2017, it had 0 buys, and 7 sales for $31.71 million activity. Ford Robert B sold $2.69M worth of stock. Fussell Stephen R sold 196,550 shares worth $9.73 million. On Wednesday, January 31 Blaser Brian J sold $1.73 million worth of Abbott Laboratories (NYSE:ABT) or 27,733 shares. Contreras Jaime sold $2.74M worth of Abbott Laboratories (NYSE:ABT) on Friday, September 22.

First Long Island Investors Llc increased its stake in Abbott Labs Com (ABT) by 48.18% based on its latest 2017Q3 regulatory filing with the SEC. First Long Island Investors Llc bought 136,242 shares as the company’s stock declined 3.42% while stock markets rallied. The hedge fund held 419,046 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $22.36M, up from 282,804 at the end of the previous reported quarter. First Long Island Investors Llc who had been investing in Abbott Labs Com for a number of months, seems to be bullish on the $103.31B market cap company. The stock increased 1.84% or $1.07 during the last trading session, reaching $59.35. About 2.18 million shares traded. Abbott Laboratories (NYSE:ABT) has risen 15.90% since February 15, 2017 and is uptrending. It has underperformed by 0.80% the S&P500.

More notable recent Abbott Laboratories (NYSE:ABT) news were published by: Gurufocus.com which released: “Capital Research Global Investors Buys Nike Inc, Abbott Laboratories, Gilead …” on February 15, 2018, also Cnbc.com with their article: “Abbott’s fourth-quarter results, 2018 profit forecast beat estimates” published on January 24, 2018, Reuters.com published: “Abbott Laboratories expected to post earnings of 73 cents a share – summary” on January 22, 2018. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: Startribune.com and their article: “St. Jude Medical delivers sales growth for Abbott Labs” published on January 25, 2018 as well as Investorplace.com‘s news article titled: “Abbott Laboratories (ABT) a Buy at recent price of $63.22, on Robust Earnings …” with publication date: January 26, 2018.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 105 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was maintained by BMO Capital Markets with “Hold” on Monday, October 2. On Wednesday, March 1 the stock rating was maintained by RBC Capital Markets with “Outperform”. Morgan Stanley downgraded Abbott Laboratories (NYSE:ABT) on Monday, January 4 to “Equal-Weight” rating. BTIG Research maintained the shares of ABT in report on Saturday, August 29 with “Buy” rating. Jefferies upgraded Abbott Laboratories (NYSE:ABT) on Monday, December 7 to “Buy” rating. As per Wednesday, January 24, the company rating was maintained by Stifel Nicolaus. The company was maintained on Friday, September 1 by RBC Capital Markets. The rating was maintained by RBC Capital Markets on Thursday, July 23 with “Outperform”. UBS initiated the shares of ABT in report on Tuesday, September 22 with “Neutral” rating. The firm has “Outperform” rating given on Tuesday, December 12 by BMO Capital Markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.